Cargando…

IgG kappa multiple myeloma with isolated central nervous system relapse

Detalles Bibliográficos
Autores principales:	Xu, Ke, Kamuriwo, Lucy, Anderson, Claire, Jasani, Parag
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Haematology Images
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9421971/ https://www.ncbi.nlm.nih.gov/pubmed/36051014 http://dx.doi.org/10.1002/jha2.469

Ejemplares similares

IgG4‐related lymphadenopathy: Benign but with rare recurrent
por: Song, Kevin, et al.
Publicado: (2021)

Triphenotypic multiple myeloma expressing kappa or lambda light chain or both
por: Liu, Yang, et al.
Publicado: (2013)

Asymptomatic leishmaniasis in a patient with relapsed multiple myeloma
por: Rubio, Lucia, et al.
Publicado: (2021)

Giant multinucleated plasma cells in relapsed plasma cell myeloma
por: Ghattas, Sylvia, et al.
Publicado: (2020)

IgA nephropathy in IgG kappa multiple myeloma
por: Couto, Maria Eduarda, et al.
Publicado: (2021)

Dutcher bodies in an IgA‐myeloma patient harbouring the FGFR3/IGH fusion
por: Manabe, Masahiro, et al.
Publicado: (2023)

A rare case of relapsed multiple myeloma with aberrant T‐cell antigen expression and skin plasmacytomas
por: Lecat, Catherine S.Y., et al.
Publicado: (2021)

Multiple myeloma with G‐CSF production mimicking chronic neutrophilic leukemia
por: Ureshino, Hiroshi, et al.
Publicado: (2021)

Central nervous system plasmablastic lymphoma evolving from polyclonal plasmacytosis
por: Khan, Umair T., et al.
Publicado: (2018)

Helicobacter cinaedi bacteremia in a patient with primary central nervous system lymphoma
por: Fujita, Mai, et al.
Publicado: (2021)

Central nervous system Langerhans cell histiocytosis and neurodegenerative syndrome responding to MEK inhibition
por: Wahba, Andrew, et al.
Publicado: (2021)

Plasmablastic myeloma progressed to plasma cell leukaemia
por: Xu, Ke, et al.
Publicado: (2021)

CD56 positive central nervous system plasmacytosis in a patient with refractory CD56 negative primary plasma cell leukaemia
por: Yong, Jun, et al.
Publicado: (2021)

Lymphoplasmacytic variant of multiple myeloma
por: Johansen, Silje, et al.
Publicado: (2022)

Myeloma‐induced leucocytoclastic vasculitis
por: De Abrew, Kanchana, et al.
Publicado: (2020)

Acquired platelet dysfunction in newly diagnosed myeloma
por: Mortimer, Joshua, et al.
Publicado: (2021)

Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results
por: Richardson, Paul G., et al.
Publicado: (2018)

Plasmacytoma/multiple myeloma type posttransplant lymphoproliferative disorder
por: Claushuis, Theodora A.M., et al.
Publicado: (2022)

Lymphoid morphology, hyperviscosity and extensive immunoglobulin deposits in myeloma
por: Sehgal, Tushar, et al.
Publicado: (2022)

Development and validation of a novel risk stratification algorithm for relapsed multiple myeloma
por: Hájek, Roman, et al.
Publicado: (2019)

A case of multiple myeloma with plasma cell cannibalism and cytophagocytosis
por: Varghese, Julia, et al.
Publicado: (2021)

Multiple myeloma presenting as a massive osteolytic lesion at the clivus
por: Sousa, Domingos, et al.
Publicado: (2020)

Gastric involvement: A rare extramedullary location of multiple myeloma
por: Pedrosa, Cláudia, et al.
Publicado: (2020)

Severe hypernatremia and hyperchloremia in an elderly patient with IgG-kappa-type multiple myeloma
por: Imashuku, Shinsaku, et al.
Publicado: (2013)

Neurolymphomatosis as a manifestation of relapsed diffuse large B‐cell lymphoma
por: Okamura‐Shiki, Ikue, et al.
Publicado: (2022)

Seborrheic keratosis (Leser‐Trélat sign) in multiple myeloma signalling disease progression
por: Jenkins, Christopher, et al.
Publicado: (2020)

Isolated bone marrow amyloid light chain amyloidosis coexisting with multiple myeloma
por: Álamo Moreno, José R., et al.
Publicado: (2023)

A case of multiple myeloma with AL amyloidosis showing giant Russel bodies
por: Mcphaden, Heather, et al.
Publicado: (2023)

IgD lambda plasma cell neoplasm with extensive AL amyloidosis
por: Al Moosawi, Muntadhar, et al.
Publicado: (2021)

A case of multiple myeloma with markedly straight lines or curved deep groove nuclei
por: He, Chang, et al.
Publicado: (2021)

Crystal‐storing histiocytes and plasma cells, crystalline corneal deposits and atypical MRI lesions in multiple myeloma
por: Khakwani, Muhammad, et al.
Publicado: (2022)

Extranodal relapse of anaplastic large cell lymphoma around the Achilles tendon masquerading as a posttraumatic hematoma
por: Joshi, Kajal, et al.
Publicado: (2021)

Secondary effects after belantamab treatment: A new anti‐B‐cell maturation antigen monoclonal antibody for multiple myeloma
por: Garrido Paniagua, Sara, et al.
Publicado: (2021)

Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma
por: Chen, Christine, et al.
Publicado: (2009)

Massive pleural effusion due to IgG-Kappa subtype multiple myeloma: A case report()
por: Arunsurat, Itthiphat, et al.
Publicado: (2019)

Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study
por: Yimer, Habte, et al.
Publicado: (2019)

Ars2‐containing bispecific, Fab‐ and IgG1‐format BAR‐bodies to target DLBCL cells
por: Kiefer, Maximilian, et al.
Publicado: (2022)

A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myeloma
por: Watanabe, Takashi, et al.
Publicado: (2016)

Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma
por: Kumar, Shaji, et al.
Publicado: (2017)

Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma
por: Jakubowiak, Andrzej J., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_9aifk688992jk29fbfftsu8rss